LPL—bound to a heparin-like heparan sulfate proteoglycan motif either on the cancer cell surface or on the luminal surface of the vascular epithelium—has been speculated to release FAs from TGRLs (Fig. 1; Extracellular Lipolysis).7,8 These FAs can then enter the cancer cells via CD36, an FA uptake channel. Here, CD44 is linked to cancer.